The MED13L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, designed to disrupt the MED13L gene. This product provides a heterogeneous pool of edited cells, allowing researchers to investigate the loss-of-function effects of MED13L in a biologically relevant lymphoma background. As polyclonal knockout cells, they reflect a range of editing events without clonal selection, making them suitable for bulk population studies where clonal artifacts are minimized. The knockout model serves as a versatile tool for probing the tumor suppressor role of MED13L and its impact on transcriptional regulation within the Mediator complex.
The Raji host cell line is a mature B lymphocyte line established from a Burkitt lymphoma, characterized by its Epstein-Barr virus (EBV)-positive status. This cell line retains many features of transformed B cells, including active B cell receptor signaling and NF-??B pathway engagement. Its derivation from an aggressive B-cell malignancy makes it an ideal model for studying oncogenic mechanisms and therapeutic responses. The EBV-driven background further adds relevance to investigations of viral?Chost interactions and their contribution to lymphomagenesis, providing a well-characterized system for functional genomics and drug discovery.
MED13L encodes a subunit of the CDK8 submodule of the Mediator complex, a key regulator of RNA polymerase II-dependent transcription. This subunit directly interacts with CDK8, CCNC, MED12, and MED13 to form a functional module that modulates transcriptional output. MED13L functions as a tumor suppressor, and its activity is influenced by upstream regulators such as NF-??B and MYC, both frequently activated in B-cell malignancies. Downstream, it controls the expression of critical target genes, including those of the Wnt/??-catenin pathway like CCND1 and MYC, as well as TGF-??-responsive genes via SMAD2 and SMAD3. Disruption of MED13L therefore alters the balance of pro-proliferative and developmental transcription programs, with significant implications for cell cycle control and differentiation.
In the Raji B-cell context, loss of MED13L is particularly relevant for dissecting the molecular underpinnings of lymphoma biology. The Mediator complex is central to integrating signals from pathways such as B cell receptor, NF-??B, and MYC, which are frequently deregulated in Burkitt lymphoma. MED13L knockout is expected to perturb the complex’s regulatory function, potentially affecting MYC-driven proliferation and NF-??B-mediated survival. This model enables the study of how transcriptional dysregulation contributes to B-cell transformation and may uncover vulnerabilities that can be exploited for therapeutic intervention. It also provides a platform to examine the interplay between EBV latency and host transcriptional machinery.
This knockout product is suitable for a wide range of research applications, including mechanistic studies of MED13L??s tumor suppressor function, transcriptional regulation by the Mediator complex, and drug screening assays for lymphoma therapies. It supports functional assays such as proliferation, apoptosis, and cell cycle analyses, as well as molecular profiling via Western blotting, RT-qPCR, and RNA-seq. Pathway-specific readouts can be achieved using Wnt/??-catenin or TGF-?? reporter systems. The polyclonal nature makes it ideal for population-level studies, including pooled CRISPR screens or bulk transcriptomic analyses. For further technical details or to discuss custom projects, please contact Ascent Research.
